Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

被引：0
|
作者：
T. Sakakida
T. Ishikawa
Y. Chihara
S. Harita
J. Uchino
Y. Tabuchi
S. Komori
J. Asai
T. Narukawa
A. Arai
H. Tsunezuka
T. Kosuga
H. Konishi
M. Moriguchi
H. Yasuda
F. Hongo
M. Inoue
S. Hirano
O. Ukimura
Y. Itoh
T. Taguchi
K. Takayama
机构：
[1] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology, Graduate School of Medical Science
[2] Kyoto Prefectural University of Medicine,Outpatient Oncology Unit, University Hospital
[3] Kyoto Prefectural University of Medicine,Department of Pulmonary Medicine, Graduate School of Medical Science
[4] Kyoto Prefectural University of Medicine,Department of Dermatology, Graduate School of Medical Science
[5] Kyoto Prefectural University of Medicine,Department of Urology, Graduate School of Medical Science
[6] Kyoto Prefectural University of Medicine,Department of Otolaryngology
[7] Kyoto Prefectural University of Medicine,Head and Neck Surgery, Graduate School of Medical Science
[8] Kyoto Prefectural University of Medicine,Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science
[9] Kyoto Prefectural University of Medicine,Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science
[10] Kyoto Prefectural University of Medicine,Division of Endocrine and Breast Surgery, Department of Surgery, Graduate School of Medical Science
来源：
Clinical and Translational Oncology | 2020年 / 22卷
关键词：
Immune-related adverse events; Programmed cell death 1 blockade; Immune checkpoint inhibitors; Antinuclear antibodies; Autoimmune diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 927
页数：8
相关论文
共 50 条
  • [21] Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer
    Mo, Dun-Chang
    Liang, Zi-Yu
    Chen, Long
    Huang, Jian-Feng
    Luo, Peng-Hui
    Wang, Han-Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (06)
  • [22] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [23] Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade
    Zheng, Chunli
    Xiao, Yue
    Chen, Chuang
    Zhu, Jinglin
    Yang, Ruijie
    Yan, Jiangna
    Huang, Ruifei
    Xiao, Wei
    Wang, Yonghua
    Huang, Chao
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (05)
  • [24] The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
    Najafi, Sajad
    Majidpoor, Jamal
    Mortezaee, Keywan
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
  • [25] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee
    Ju Yeon Lee
    Heejin Lim
    Sang Hyung Lee
    Yu Jeong Moon
    Hyo Jeong Pyo
    Seong Eon Ryu
    Woori Shin
    Yong-Seok Heo
    Scientific Reports, 7
  • [26] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Lee, Hyun Tae
    Lee, Ju Yeon
    Lim, Heejin
    Lee, Sang Hyung
    Moon, Yu Jeong
    Pyo, Hyo Jeong
    Ryu, Seong Eon
    Shin, Woori
    Heo, Yong-Seok
    SCIENTIFIC REPORTS, 2017, 7
  • [27] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    MODERN PATHOLOGY, 2015, 28 : 123A - 123A
  • [28] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [29] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [30] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
12345